Mineralys Therapeutics, Inc. presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The data were presented during the Late-Breaking Posters session at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held in Philadelphia from November 2-5. In this new analysis, investigators identified a population of responders to lorundrostat who experienced a median reduction in systolic blood pressure (BP) of 32 millimeters of mercury (mmHg). Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.1 USD | -3.35% | -8.37% | +40.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.12% | 622M | |
+63.16% | 62.59B | |
-1.95% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.34% | 26.21B | |
-22.03% | 19.09B | |
+3.44% | 13.08B | |
+25.39% | 12.26B | |
+27.37% | 12.05B |
- Stock Market
- Equities
- MLYS Stock
- News Mineralys Therapeutics, Inc.
- Mineralys Therapeutics, Inc. Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting